The FDA last week approved Eli Lilly’s Mounjaro injection for the treatment of type 2 diabetes. The drug is the first GIP and GLP-1 receptor agonist in the diabetes market basket, and can also treat obesity. In a 2021 study, Mounjaro beat out Novo Nordisk’s top-selling Ozempic in patients’ blood sugar levels and overall weight loss. For the treatment of diabetes, Ozempic holds covered or better status for 97% of all insured lives under the pharmacy benefit. 40.5% of covered lives have preferred access to Ozempic without utilization management restrictions. As a treatment for obesity, Ozempic is marketed as Wegovy, and holds covered or better status for 49% of all insured lives under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 5/18/22